App-Quantinova.ai

Analysis of patients (pts) with in-transit metastases treated with nivolumab (NIVO) or ipilimumab (IPI) in CheckMate 238.

James Larkin - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Melanoma

Ipilimumab

The safety and efficacy of PEN-221 somatostatin analog (SSA)-DM1 conjugate in patients (PTS) with advanced GI mid-gut neuroendocrine tumor (NET): Phase 2 results.

Daniel M. Halperin - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Neuroendocrine tumors

Somatostatin

Clinical activity of fianlimab (REGN3767), a human anti-LAG-3 monoclonal antibody, combined with cemiplimab (anti-PD-1) in patients (pts) with advanced melanoma.

Omid Hamid - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Melanoma

N/A

Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 ≥ 50%: Results from EMPOWER-Lung 1 study.

Mahmut Gumus - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

N/A

Treatment outcomes in patients (pts) with melanoma brain metastases (MBM) treated with systemic therapy: A systematic literature review (SLR) and meta-analysis.

Hussein Abdul-Hassan Tawbi - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Brain metastasis

Ipilimumab

Proliferation index and survival in men with prostate cancer starting long-term androgen deprivation therapy in the STAMPEDE clinical trial.

Larissa Mendes - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Androgen Tear

An international, multicenter, real-world analysis of epithelial ovarian cancer treatment and outcomes.

Geoff Hall - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Ovarian cancer

N/A

A comparison of the burden of thyroid cancer amongst European Union 15+ countries, 1990-2017: Estimates from the Global Burden of Disease Study.

James Schuster-Bruce - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Thyroid Cancer

N/A

Outcomes of immune checkpoint inhibitor-mediated colitis: Multicenter cohort study.

Hamzah Abu-Sbeih - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

Entyvio

Clinical outcomes in patients relapsed/refractory after ≥ 2 prior lines of therapy for follicular lymphoma: A systematic literature review and meta-analysis.

Steve Kanters - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Follicular lymphoma

N/A

Real-world outcomes from the systemic use of CDK 4/6 inhibitors (CDKIs) in the management of ER positive (+) HER2 negative (-) metastatic breast cancer (mBC).

Karen DeSouza - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Abemaciclib

Automated immunostaining-free prediction of breast carcinoma ER and PR status, Ki67 count, patient therapy stratification index and quantification of prognostic quiescence burden in TNBC from pretreatment H&E stained histopathology images in breast cancer.

Tathagata Dasgupta - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Association of C-reactive protein (CRP) with efficacy of avelumab + axitinib (A + Ax) in advanced renal cell carcinoma (aRCC): Long-term follow-up results from JAVELIN Renal 101.

Yoshihiko Tomita - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic Renal Cell Cancer

Inlyta

Systematic literature review of the real-world burden and use of chemotherapies for treatment of advanced or recurrent endometrial carcinoma.

Qi Zhao - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Endometrial Cancer

Carboplatin

Polatuzumab vedotin (Pola) + rituximab (R) + lenalidomide (Len) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Primary analysis of a phase 1b/2 trial.

Catherine S. Magid Diefenbach - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

Polatuzumab vedotin

Disparities in reporting and representation of women, older adults and racial minorities in immune checkpoint inhibitor (ICI) clinical trials.

Irbaz Bin Riaz - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Analysis of clinical and genomic subgroups from the JAVELIN Bladder 100 trial.

Thomas Powles - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Advanced Urothelial Carcinoma

Carboplatin

Improving the prediction of surgical outcome at secondary cytoreduction in patients with ovarian cancer: Results from retrospective part of HELP-ER study NOGGO TR2/ENGOT OV47-TR.

Ioana Braicu - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gynaecological cancer

N/A

Pembrolizumab plus enzalutamide for enzalutamide-resistant metastatic castration-resistant prostate cancer (mCRPC): Updated analyses after one additional year of follow-up from cohorts 4 and 5 of the KEYNOTE-199 study.

Julie N Graff - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Pembrolizumab

Limb volume reduction and infection outcomes following vascularized lymph node transfer for cancer treatment-related lymphoedema: A systematic review and meta-analysis.

Joseph Alexander Ward - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Bacterial Skin Infection

N/A

Filters

45280 Abstracts